Back to top
more

Prothena (PRTA)

(Delayed Data from NSDQ)

$24.79 USD

24.79
541,580

+0.82 (3.42%)

Updated Jul 25, 2024 04:00 PM ET

After-Market: $24.78 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Biogen (BIIB) Down on Report of Death in Alzheimer's Study

Investor confidence in Biogen (BIIB) is rattled following reports of a study participant's death who was administered its Alzheimer's disease (AD) antibody in clinical studies.

Prothena (PRTA) Earns Milestone Payment From Novo Nordisk

Prothena (PRTA) earns a $40 million milestone payment from Novo Nordisk following the progress of NNC6019 in a phase II study for the treatment of ATTR cardiomyopathy.

Prothena's (PRTA) Q3 Earnings Miss, Revenues Decline Y/Y

Prothena (PRTA) incurs a loss in the third quarter while revenues miss estimates.

Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -212.90% and 94.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Annovis (ANVS) Gains on FDA Authorization for AD Study

Annovis (ANVS) shares jump following the FDA's authorization to proceed with the phase II/III clinical study of lead candidate buntanetap in moderate Alzheimer's Disease (AD).

Ekta Bagri headshot

LLY & PRTA in Spotlight on BIIB-Eisai's AD Drug Data

The success of Biogen (BIIB)-Eisai's AD candidate in a big phase III study makes investors optimistic about the prospects of other AD candidates as well.

Prothena (PRTA) Down 16.9% Since Last Earnings Report: Can It Rebound?

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus

Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -72.55% and 93.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Why Is Epizyme (EPZM) Up 51.7% Since Last Earnings Report?

Epizyme (EPZM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Prothena (PRTA) Q1 Earnings Beat, Pipeline Progress in Focus

Prothena beats on earnings and revenues in the first quarter of 2022. The company's progress with its AD pipeline is encouraging.

Prothena (PRTA) Reports Q1 Loss, Tops Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 8.24% and 401.30%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) Stock Gains 51% in a Year: What Lies Ahead?

Prothena (PRTA) has had a phenomenal run in the past year, primarily due to its promising pipeline for AD.

Prothena (PRTA) IND Application Gets FDA Clearance for AD

Prothena (PRTA) application for evaluating PRX012 for the treatment of Alzheimer's disease (AD) gets FDA clearance.

Prothena (PRTA) Q4 Earnings Beat, Pipeline Progress in Focus

Prothena beats on earnings and revenues in the fourth quarter of 2021. The company's progress with its AD pipeline is encouraging.

Prothena (PRTA) Reports Q4 Loss, Tops Revenue Estimates

Prothena (PRTA) delivered earnings and revenue surprises of 4.05% and 324.64%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Prothena (PRTA) Report Negative Q4 Earnings? What You Should Know

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ekta Bagri headshot

5 Biotech Stocks That More Than Doubled This Year

The biotech sector has been in focus through 2021 as vaccine makers like Moderna (MRNA) BioNTech (BNTX), and other companies like Dynavax (DVAX), Prothena (PRTA) and Intellia (NTLA) put up an exemplary performance.

Cassava (SAVA) Down on Report of SEC Investigation Into AD Program

Cassava (SAVA) tanks on reports of an investigation by the SEC related to data reports on its AD candidate.

Prothena (PRTA) Q3 Earnings Miss, Pipeline Progress in Focus

Prothena misses on earnings and revenues in the third quarter of 2021. Nevertheless, the company's progress with its AD pipeline is encouraging.

Prothena (PRTA) Q3 Earnings and Revenues Miss Estimates

Prothena (PRTA) delivered earnings and revenue surprises of -5.33% and -0.64%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

VRTX vs. PRTA: Which Stock Is the Better Value Option?

VRTX vs. PRTA: Which Stock Is the Better Value Option?

Prothena (PRTA) to Report Q3 Results: Wall Street Expects Earnings Growth

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Prothena (PRTA) Riding High on Alzheimer's Disease Pipeline

Prothena (PRTA) has promising candidates for Alzheimer's disease in its pipeline. The successful development of the candidates will be a big boost for the company.

VRTX vs. PRTA: Which Stock Should Value Investors Buy Now?

VRTX vs. PRTA: Which Stock Is the Better Value Option?